Preemptive drug combo may shield new kidneys from FSGS return
NCT ID NCT03763643
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether giving the drug rituximab along with a blood-filtering procedure called plasmapheresis right before a kidney transplant could prevent focal segmental glomerulosclerosis (FSGS) from recurring. The trial enrolled 21 children and adults with FSGS who were getting a kidney transplant. The main goal was to see if this approach was feasible, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rituximab
What this could lead to
If it works, this could point toward a way to prevent FSGS from returning after a kidney transplant, helping patients keep their new kidney longer.
What could go wrong
This is a very early pilot study with only 21 participants, so results may not apply to everyone. The treatment also carries risks like infection from immune suppression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Colorado
Aurora, Minnesota, 80045, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Cincinnati Children's Hospital
Cincinnati, Ohio, 45229, United States
-
Duke University
Durham, North Carolina, 27708, United States
-
Lurie Children's Hospital
Chicago, Illinois, 60611, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
-
University of Alabama
Tuscaloosa, Alabama, 35487, United States
-
University of California at Davis
Davis, California, 95616, United States
-
University of Cincinnati
Cincinnati, Ohio, 45221, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States